Vivoryon Therapeutics « Terug naar discussie overzicht

Vivoryon is de naam. Daarom nieuw draadje

6.265 Posts, Pagina: « 1 2 3 4 5 6 ... 104 105 106 107 108 109 110 111 112 113 114 ... 310 311 312 313 314 » | Laatste
Ookaanwezigbij...
0
DeZwarteRidder
0
quote:

Ookaanwezigbij... schreef op 29 augustus 2020 16:07:

[...]Ow Ja......1,50
Het is slechts een kwestie van tijd.
Muisje
0
quote:

DeZwarteRidder schreef op 30 augustus 2020 09:21:

[...]
Het is slechts een kwestie van tijd.
Hahaha wat een comedy..
Amarillo
0
Ff wat serieus nieuws van de concurrentie mensen: Neuralink van Elon Musk heeft een chip geimplanterrd in het brein van een varken om zo hersenaandoeningen te kunnen bestrijden waaronder ook Altzheimer..zit ook hier in de testfase en nog bij een varken..oke,oke..maar die moeten we ook ff niet uitvlakken vind in
K. Wiebes
0
Reactie van Gretchen (dat rood moet je er zelf maar even bij verzinnen):

Dear K. Wiebes,

Please see below a transcript of your questions from our call on Friday and the replies
in dark red from Vivoryon. Please contact me with any further questions.

“Being that dissenting shareholders would receive €9.00 for their shares, wouldn’t a
large proportion of shareholders prefer that option since the shares are trading
significantly below €9?”

--If shareholders holding more than 2% of the voting rights in the aggregate have an
objection recorded in the shareholders’ meeting, the conversion and thus the
compensation offer will not be implemented.
Therefore, if too many shareholders try to use this proposal as an exit option, no
compensation will be paid.

“For example, MorphoSys has sold some of their position and they still own 10%
of the shares, therefore they would welcome the chance to liquidate their shares
for the €9.”

--Again, if they would dissent at such a level (i.e. more than 2%), there is no way
the transaction goes through and thus, no compensation would be paid.
Therefore, the compensation offer does not present an exit option, in particular
not for major shareholders.

“Is the management therefore convinced that MorphoSys would not dissent
to the transaction?”

-- No major shareholder has agreed to the transaction in advance. However,
given the advantages for the company and its shareholders of the proposed
N.V. structure, the management believes that all major shareholders will vote
in favour of the proposed resolution. The legal form of an N.V. would reduce
administrative efforts for both the Company and its shareholders, would
facilitate the access to a broader investor base including in the U.S.

“Since the company requested a valuation analysis to come to the € 8.87 fair
value of the shares, can Vivoryon please post that analysis report on the website?”

-- The valuation report is part of the conversion report and will be published
together with the invitation and the other documents relating to the General
Meeting on or around 3 September 2020.

Best regards,
Gretchen

Gretchen L.P. Schweitzer
Managing Director
Trophic | Communications GmbH

Nog even een vraag teruggestuurd:
Het voorstel moet dus met 98% van de stemmen worden aangenomen?
DeZwarteRidder
0
quote:

K. Wiebes schreef op 31 augustus 2020 14:39:

Reactie van Gretchen (dat rood moet je er zelf maar even bij verzinnen):

Dear K. Wiebes,

Please see below a transcript of your questions from our call on Friday and the replies in dark red from
Vivoryon. Please contact me with any further questions.

“Being that dissenting shareholders would receive €9.00 for their shares, wouldn’t a large proportion of
shareholders prefer that option since the shares are trading significantly below €9?”

--If shareholders holding more than 2% of the voting rights in the aggregate have an objection recorded
in the shareholders’ meeting, the conversion and thus the compensation offer will not be implemented.
Therefore, if too many shareholders try to use this proposal as an exit option, no compensation will be
paid.

“For example, MorphoSys has sold some of their position and they still own 10% of the shares, therefore
they would welcome the chance to liquidate their shares for the €9.”

--Again, if they would dissent at such a level (i.e. more than 2%), there is no way the transaction goes
through and thus, no compensation would be paid. Therefore, the compensation offer does not present
an exit option, in particular not for major shareholders.

“Is the management therefore convinced that MorphoSys would not dissent to the transaction?”

-- No major shareholder has agreed to the transaction in advance. However, given the advantages
for the company and its shareholders of the proposed N.V. structure, the management believes that
all major shareholders will vote in favour of the proposed resolution. The legal form of an N.V. would
reduce administrative efforts for both the Company and its shareholders, would facilitate the access
to a broader investor base including in the U.S.

“Since the company requested a valuation analysis to come to the € 8.87 fair value of the shares,
can Vivoryon please post that analysis report on the website?”

-- The valuation report is part of the conversion report and will be published together with the
invitation and the other documents relating to the General Meeting on or around 3 September
2020.
Best regards,
Gretchen
Gretchen L.P. Schweitzer
Managing Director
Trophic | Communications GmbH
Nog even een vraag teruggestuurd:
Het voorstel moet dus met 98% van de stemmen worden aangenomen?
Weet je het nou nog niet.....????
K. Wiebes
0
Dear K. Wiebes,

Please see the answers from Vivoryon to your questions below in red.

- So the proposal will need 98% of the votes?
As per German law, to be ratified the proposal will need a majority of 75% of
the votes cast at the AGM, however, the proposal will not be implemented if
for more than 2% in total of the overall voting rights (i.e. more than 399,509
shares) objections are recorded in the minutes of the meeting.

- And if not: how much money is Viv. willing to spend on compensation?
The maximum compensation would correspond to a maximum of 2% of the
shares (out of 19,975,482) at a compensation amount of EUR 9 per share.
Details will be published on September 3rd on the company’s webpage.

Should there be additional questions, please let me know.

Best,
Gretchen
dulieu
0
DeZwarteRidder
0
quote:

@ out of the blue schreef op 3 september 2020 16:06:

En weg is de mooie stijging. Wat gebeurde daar?
Dumpie, dumpie natuurlijk.

Eerst de koers wat omhoogduwen en dan dumpen.
Muisje
0
Sommige hier zitten echt te wachten tot ze de boel weer naar beneden kunnen .. lachwekkend gewoon!
DeZwarteRidder
0
quote:

Muisje schreef op 3 september 2020 16:15:

Sommige hier zitten echt te wachten tot ze de boel weer naar beneden kunnen .. lachwekkend gewoon!
Pas maar op.....!!!
Bijlage:
Kuiken
0
VIVO heeft onderneming laten waarderen door een Zwitsers bedrijf Venture Valuation( oa gefinancierd door Novartis en European Investment Bank) Het bedrijf is actief in de bio/pharma hoek.
Het rapport doorgelezen en conclusie:

Ze zien een beperkte kans van slagen van VIVO. Percentages tussen de 2,7 en 11% voor de twee hoofd pipeline-producten.
Kans van slagen neemt toe naarmate Phase II overgaat naar III en naar approval.
Tijdstip van implementatie 2027/2029, maar mochten er traject-versnellingen worden afgegeven
vanwege gunstige onderzoeksresultaten, kan dat ook eerde worden.
Het is zeker geen Hosanna-rapport Onderzoekers zien veel beren op de weg.
Maar na vergelijking met vele gelijksoortige ondernemingen en ook het afwegen van de concurrentie, geven ze VIVO TWEE,
keer de waarde mee van wat er nu op de koersborden staat.

beetje doorklikken op VIVO-site en u kunt het zelf lezen.
K. Wiebes
0
quote:

DeZwarteRidder schreef op 3 september 2020 16:10:

[...]
Dumpie, dumpie natuurlijk....
Och joh; wát kan jou 't schelen?

Koop er nu maar gewoon 'n stuk of 300 en stof ze over 'n jaartje
of 3 af.

Vanaf pag. 131:
www.vivoryon.com/wp-content/uploads/2...
[verwijderd]
0
quote:

DeZwarteRidder schreef op 3 september 2020 16:10:

[...]
Dumpie, dumpie natuurlijk.

Eerst de koers wat omhoogduwen en dan dumpen.
Hoest met je Galapagos?
6.265 Posts, Pagina: « 1 2 3 4 5 6 ... 104 105 106 107 108 109 110 111 112 113 114 ... 310 311 312 313 314 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 23 apr 2024 16:02
Koers 0,754
Verschil +0,184 (+32,28%)
Hoog 0,825
Laag 0,613
Volume 2.160.449
Volume gemiddeld 597.373
Volume gisteren 546.850

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront